Schrodinger Working With Centessa Pharmaceuticals Subsidiary to Discover Novel Therapeutics for Various Sleep Disorders

8:52AM ET 10/18/2021 MT Newswires
Schrodinger (SDGR) said Monday it is working with Centessa Pharmaceuticals' (CNTA) Orexia Therapeutics subsidiary to discover novel therapeutics for various sleep disorders, including narcolepsy.

Under the terms of the partnership, Orexia Therapeutics will be responsible for preclinical research activities, clinical development and commercialization of future product candidates discovered under the collaboration.

Meanwhile, Schrodinger will receive an upfront software access payment and may become eligible to receive certain preclinical, development, regulatory and commercial milestone payments, as well as low single-digit royalties on global net sales, according to a statement.